NGM Bio subject of take-private bid by institutional investor The Column Group
NGM Bio, with a spate of clinical setbacks and financial woes in recent years, has received an unsolicited acquisition bid from shareholder The Column Group …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.